Monitor quarterly disclosures of shares sold under the ATM to gauge actual dilution. The company's cash runway extends to mid-2028 per Q3 2026 guidance, but the ATM signals ongoing capital needs for clinical trials of FT819 and FT839.
Drugs in focus
FATE drug pipeline →FT819
● Neutral Named in this 424B5- Impact
- Phase
- Phase 2
- Time to market
- FT819 is in Phase 2 testing (RECLAIM-LN, a potentially registrational trial) that began enrolling in August 2026. If successful, an FDA submission could be several years away, likely in 2028-2029 at the earliest.
- Next catalyst
- None dated
What to watchThe next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $1.28entry
- T+1 · 18h ago −10.94%α −9.03% · $1.14
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fate Therapeutics filed a 424B5 prospectus supplement establishing a new $100M at-the-market (ATM) equity facility with Leerink Partners, replacing a prior ATM with Jefferies. The company had $139.1M in cash as of September 30, 2026 and is a pre-revenue clinical-stage biotech. The ATM provides ongoing capital access for pipeline development but signals continued cash needs.
Key Financial Metrics
Key Facts
- ATM facility of up to $100,000,000 in common stock with Leerink Partners as sales agent
- Commission rate of up to 3.0% of gross proceeds
- 106,155 shares already sold under prior ATM for $176,811.77 in gross proceeds
- Last reported sale price on November 11, 2026 was $1.61 per share
- Cash, cash equivalents and short-term investments of $139.1M as of September 30, 2026
- Net loss of $0.25 per share in Q3 2026, no collaboration revenue
- Prior ATM with Jefferies LLC terminated in connection with new Leerink agreement
Financial Impact
Up to $100,000,000 in potential equity issuance; maximum dilution of up to 62,111,801 shares at $1.61/share (51% of current 121.5M shares outstanding)
Risk Factors
- Potential dilution of up to 51% of current shares outstanding if full $100M is sold at current prices
- Pre-revenue clinical-stage biotech with no approved products and ongoing net losses
- ATM sales at various prices may pressure stock price over time
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-458736 |
| Document: 0001193125-26-458736-index-headers.html | 0001193125-26-458736 |
| Document: 0001193125-26-458736-index.html | 0001193125-26-458736 |
| Document: 0001193125-26-458736.txt | 0001193125-26-458736 |
Track record
21 reports on FATE
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Viewing Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers